Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Susvimo EU recommendation gives Roche a new weapon in the battle for longer-lasting eye treatments
Roche moves Susvimo toward EU approval as its refillable eye implant targets injection burden and strengthens a CHF 2.1 billion retinal franchise.
Abbott adds colorectal cancer blood test to Cologuard portfolio after Freenome FDA win
Freenome wins FDA approval for SimpleScreen CRC, triggering a $100 million Abbott payment and setting up a fall U.S. launch.
Incyte (Nasdaq: INCY) Q2 2026 revenue jumps 38% as CMS Opzelura settlement lifts headline growth
Incyte Q2 revenue jumped 38% on a $246m CMS Opzelura benefit, but the underlying growth line and $1.27bn Vega charge redraw the 2026 investment case.
Corbus Pharmaceuticals (NASDAQ: CRBP) lands FDA clearance for TEMPO-1 as CRB-701 enters Phase 3
CRB-701 delivered a 42.9% ORR in 2L OPSCC. Corbus Pharmaceuticals must now reproduce it in a 250-patient TEMPO-1 trial that starts enrolling in September.
Can Secretome Therapeutics turn its expanded leadership team into a Duchenne breakthrough?
Secretome Therapeutics has recruited experienced clinical, operational, medical affairs and finance executives as the private biotechnology company prepares to move STM-01 deeper into development for Duchenne muscular dystrophy-associated cardiomyopathy. The appointments indicate that Secretome is building the organisation required for late-stage trials and potential commercialisation, although the ultimate value of that infrastructure will depend on whether STM-01 produces convincing clinical evidence.
Can Elisabeth Svanberg help Medincell turn clinical progress into durable value?
Medincell wants pharmaceutical executive Elisabeth Svanberg to join its board and lead its remuneration and nomination committee. The proposal comes as the French biotechnology company moves from platform development towards recurring royalty growth and potential multi-product commercialisation.
Can InstaMed Pharmaceuticals turn needle-free peptide strips into a credible global platform?
The Salt Lake City biotechnology company is moving its formulation specialist into the top job as it attempts to turn oral peptide films into a scalable international platform.
Aroa Biosurgery has the products and the cash. Can its new US team deliver the next growth phase?
Aroa Biosurgery expands its US commercial leadership as Myriad growth accelerates, but FY27 investment must translate into stronger sales productivity.
Stoke Therapeutics has enrolled its pivotal Dravet trial, but what must the August 3 call prove?
Stoke Therapeutics will discuss its second-quarter performance on August 3 after completing enrollment in the pivotal EMPEROR trial. Investors will be looking beyond quarterly revenue to assess spending, regulatory execution and preparations for a possible zorevunersen launch.
Neuraxpharm Group’s leriglitazone bet advances as European regulators back a narrow pediatric label
Minoryx Therapeutics revives its €258 million Neuraxpharm deal as leriglitazone moves closer to a narrow European rare-disease launch.